Last reviewed · How we verify
Dabigatran, Ticagrelor, ASA
At a glance
| Generic name | Dabigatran, Ticagrelor, ASA |
|---|---|
| Sponsor | Medical University of Vienna |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
- Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
- Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis (NA)
- Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4) (PHASE4)
- Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI (PHASE4)
- Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)
- Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dabigatran, Ticagrelor, ASA CI brief — competitive landscape report
- Dabigatran, Ticagrelor, ASA updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI